| | | I have 40% of my portfolio in healthcare. The only medical products stock I am long is BDX, which I am up about 7% since I bought in December. TMO, WAT, A and DHR are all out of my league. They are selling for multiples in the mid to upper 20's. In the case of TMO, there is 10%-15% upside, technically speaking. But I don't go long high multiple stocks and by doing so, I've kept out of trouble this year while my portfolio is up close to 8%.
I am a big fan of BDX. The stock is selling for twenty times next year's earnings, which is slightly rich for me, but I like the chart, upper management and above all, the fundamentals of the company. I have a price target of $310 for this low beta stock, which has held up quite well throughout the volatile times.
I am a value player who is long BDX, DGX, MRK, PFE, AMGN, BMY, JNJ, ABC, CI and HUM in the sector. Some are significant positions.
I am not to impressed with IHI or most medical products stocks. I have strict valuation criterions unless the stock is a dominant player ( or the potential to be one) and massive cash cow. MSFT and GOOG are dominant market players and deserve a premium valuation. Actually, GOOG is selling at a cheaper multiple than the medical product stocks you referred to.
There is massive insider selling in TMO.
My prime concern is with not losing my Ass. If I can focus on that, profits will come naturally. |
|
